Munich (Germany) – August 29, 2013 – BICOLL Group announces today the successful application of its technology for the identification of ligands of a specific orphan target. As described in a new publication in the Journal of Biomolecular Screening, a …
Munich, Germany – May 11, 2011 – BICOLL GmbH, a biopharmaceutical drug discovery company specializing in high-tech natural product chemistry and medicinal chemistry to identify novel small molecules for drug discovery and related innovative fields, will be responsible for roughly …
European Biopharmaceutical Review, January 2011, p.52 Kai Lamottke at Bicoll GmbH, Christophe Ripoll at Naturalpha and Robert Walczak at Genfit SA ask if the biotech industry can afford to turn away from natural product drug discovery research. One of the …
Press Release of Bicoll’s OLNORME II partner Genfit SA The OLNORME II Consortium, for which GENFIT is the leader, is focused on the development of a new class of drug candidates for the prevention and treatment of cardiometabolic diseases with …
Munich (Germany), Lille (France) – September 1, 2009 – BICOLL GmbH, a biopharmaceutical drug discovery company specializing in high-tech natural product chemistry to identify novel small molecules for drug discovery and related innovative fields and GENFIT SA (Alternext: ALGFT; ISIN: …
Munich, Germany – July 3, 2007 – The Bicoll GmbH, a biopharmaceutical company specializing in high-tech natural product chemistry to identify novel small molecules for drug discovery and related innovative fields, today announces the signing of a collaboration agreement with …